Results 21 to 30 of about 16,087 (221)

Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial

Cardiovascular Diabetology, 2022
Background Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) lower blood pressure (BP). When SGLT2i and GLP-1RA are combined, synergistic effects on BP have been observed. The mechanisms underlying
Charlotte C. van Ruiten, Mark M. Smits, Megan D. Kok, Erik H. Serné, Daniël H. van Raalte, Mark H. H. Kramer, Max Nieuwdorp, Richard G. IJzerman   +7 more
doaj   +1 more source

Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor

Frontiers in Pharmacology, 2022
Background: Elevated soluble urokinase plasminogen activator receptor (suPAR) is highly associated with increased risk of diabetic complications. Dapagliflozin is a drug inhibiting the sodium-glucose co-transporter 2 in the kidney to decrease blood ...
Viktor Rotbain Curovic, Morten B. Houlind, Tine W. Hansen, Jesper Eugen-Olsen, Jens Christian Laursen, Mie K. Eickhoff, Frederik Persson, Peter Rossing, Peter Rossing   +8 more
doaj   +1 more source

Exploring the effect of dapagliflozin on coronary inflammation in type 2 diabetes patients based on the coronary artery perivascular fat attenuation index

Cardiovascular Diabetology
Background The pericoronary fat attenuation index (FAI) is a novel biomarker that serves as an indicator of coronary artery inflammation. Dapagliflozin has become an important component of standard treatment for type 2 diabetes because of its ...
Xuehua Liu, Tian Zhang, Rong Fu, Dan Liu, Jingyi Zhang, Qing Hu, Guangyao Song, Luping Ren   +7 more
doaj   +1 more source

Production, use, transfer of prodrug substances, and direct or indirect infringement of the patent: Focusing on the dapagliflozin formate case

Journal of Intellectual Property
This study explored whether the utilization of dapagliflozin formate, a dapagliflozin prodrug, constitutes direct (including literal infringement and infringement under the doctrine of equivalents) and indirect infringement, against a patent covering a ...
Kwanshik Kim
doaj   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Dapagliflozin Ameliorates Diabetic Kidney Disease via Upregulating Crry and Alleviating Complement Over-activation in db/db Mice

Frontiers in Pharmacology, 2021
Sodium-glucose cotransporter 2(SGLT2) inhibitors show prominent renal protective effect in diabetic kidney disease (DKD), anti-inflammatory effect being one of its key mechanisms.
Dong-Yuan Chang, Dong-Yuan Chang, Dong-Yuan Chang, Xiao-Qian Li, Xiao-Qian Li, Xiao-Qian Li, Min Chen, Min Chen, Min Chen, Ming-Hui Zhao, Ming-Hui Zhao, Ming-Hui Zhao   +11 more
doaj   +1 more source

Comparative efficacy of GLP‐1 RA, tirzepatide and SGLT‐2 inhibitors in metabolic liver disease: A network meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aim Metabolic liver disease, including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis, is a major cause of chronic liver dysfunction worldwide, creating an urgent need for effective treatments. This systematic literature review (SLR) and network meta‐analysis (NMA) systematically reviews and compares the efficacy and safety ...
Andrej Belančić, Christina Antza, Anastasios Poutachidis, Smaro Palaska, Elvira Meni Maria Gkrinia, Andrea Katrin Faour, Yusuf Ziya Sener, Seher Sener, Rehena Sultana   +8 more
wiley   +1 more source

Dapagliflozin attenuates diabetes-induced diastolic dysfunction and cardiac fibrosis by regulating SGK1 signaling

BMC Medicine, 2022
Background Recent studies have reported improved diastolic function in patients administered sodium-glucose cotransporter 2 inhibitors (SGLT2i). We aimed to investigate the effect of dapagliflozin on left ventricular (LV) diastolic function in a diabetic
Seul-Gee Lee, Darae Kim, Jung-Jae Lee, Hyun-Ju Lee, Ro-kyung Moon, Yong-Joon Lee, Seung-Jun Lee, Oh-Hyun Lee, Choongki Kim, Jaewon Oh, Chan Joo Lee, Yong-ho Lee, Seil Park, Ok-Hee Jeon, Donghoon Choi, Geu-Ru Hong, Jung-Sun Kim   +16 more
doaj   +1 more source

Results of the DAPA-CKD trial and their impact on clinical practice

Mìžnarodnij Endokrinologìčnij Žurnal, 2023
Chronic kidney disease (CKD) is a growing medical and social problem in the world. Data from population base stu­dies demonstrate an increase in the prevalence of CKD and mortality. One of the causes is an increase in the number of patients with diabetes.
O.V. Bilchenko
doaj   +1 more source